Gastrointestinal adverse events associated with use of biologic therapies available for psoriasis: A systematic review of pharmacovigilance studies - 09/10/24
Doi : 10.1016/j.jaad.2024.09.022
Siddhartha Sood, HBSc a, Nawar Tarafdar, BSc b, Jonah Perlmutter, BSc a, Khalad Maliyar, MD c, Muskaan Sachdeva, MD c, Asfandyar Mufti, MD c, d, Jensen Yeung, MD c, d, e, f, ⁎ 
a Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
b Faculty of Medicine, Western University, London, Ontario, Canada
c Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
d Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
e Probity Medical Research, Waterloo, Ontario, Canada
f Department of Dermatology, Women's College Hospital, Toronto, Ontario, Canada
∗Correspondence to: Jensen Yeung, MD, Division of Dermatology, Women's College Hospital, 76 Grenville St, 5th floor, Toronto, Ontario M5S 1B2, CanadaDivision of DermatologyWomen's College Hospital76 Grenville St5th floorTorontoOntarioM5S 1B2Canada
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Wednesday 09 October 2024
Key words : adverse event, biologic, gastrointestinal, pharmacovigilance, psoriasis, systematic review
| Drs Yeung and Mufti are co-senior authors. |
|
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?